International registry for Blastic Plasmacytoid Dendritic Cell Neoplasm
Official title: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Run by Immune Oncology Research Institute · NCT05430971 · Data updated 2026-11-12
This study is creating a global database for people with Blastic Plasmacytoid Dendritic Cell Neoplasm to gather information on their experiences and treatments to help improve care for this rare cancer.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Immune Oncology Research Institute Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 22 sites (Miami, Florida and 21 other locations) |
| Status | Recruiting |
| Started | July 1, 2022 |
| Main results expected | July 2032 |
| Study ends | July 2032 |
| Registry record updated | June 5, 2026 |
| Trial ID | NCT05430971 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm.
✕Probably not a fit
Patients without a confirmed diagnosis of BPDCN will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to create a comprehensive international registry for patients diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare hematologic malignancy. It will collect data on clinical presentations, diagnostic criteria, treatment regimens, and patient outcomes to better understand the disease. The registry will facilitate collaboration among various centers to evaluate prognostic factors and develop data-driven treatment recommendations. By gathering extensive information, the study seeks to address the lack of consensus on optimal treatment strategies for BPDCN.
Why it matters
Potential benefit: If successful, this registry could lead to improved treatment strategies and outcomes for patients with BPDCN.
How similar studies have gone: While there have been studies on BPDCN, this registry approach is novel and aims to fill a significant gap in data collection for this rare condition.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of BPDCN * Signed informed consent form for prospective patients Exclusion Criteria: \-
Where it's running
-
Sylvester Comprehensive Cancer Center, University of Miami
Miami, Florida, United States Recruiting -
Moffitt Cancer Center
Tampa, Florida, United States Recruiting -
Seattle Children's Cancer and Blood Disorders Center
Seattle, Washington, United States Recruiting -
Hematology Center named after prof. R. Yeolyan
Yerevan, Armenia Recruiting -
University of Calgary
Calgary, Alberta, Canada Recruiting -
Children's Hospital of Eastern Ontario, University of Ottawa
Ottawa, Ontario, Canada Recruiting
Show 16 more locations
-
Cyprus Society of Haematology
Nicosia, Cyprus Recruiting -
Oncology Center, Mansoura University Faculty of Medicine
Al Mansurah, Egypt Recruiting -
M. Iashvili Children's Central Hospital
Tbilisi, Georgia Recruiting -
Department of Medical Oncology, Dr. B.R.A Institute Rotary Cancer Hospital, All India Institute of Medical Sciences
New Delhi, India Recruiting -
Pediatric Hematology Oncology, Children's Welfare Teaching Hospital, Medical City, College of Medicine, University of Baghdad
Baghdad, Iraq Recruiting -
University of Perugia - Azienda Ospedaliera Perugia
Perugia, Italy Recruiting -
Department of Biomedicine and Prevention, University of Rome Tor Vergata
Roma, Italy Recruiting -
King Hussein Cancer Center (KHCC)
Amman, Jordan Recruiting -
Department of hematology, Kuwait Cancer Control Center
Kuwait City, Kuwait Recruiting -
Fundeni Clinical Institute, Department of Acute Leukemia
Bucharest, Romania Recruiting -
China Medical University Children's Hospital
Taichung, Taiwan Recruiting -
Turkish Pediatric Cancer Registry
Ankara, Turkey (Türkiye) Recruiting -
Istanbul University, Oncology Institute
Istanbul, Turkey (Türkiye) Recruiting -
University of Health Sciences, Umraniye Research and Education Hospital, Pediatric Hematology and Oncology Department, Pediatric Bone Marrow Transplantation Unit
Istanbul, Turkey (Türkiye) Recruiting -
Broomfield Hospital, Haematology Mid and South Essex University Hospitals Group
Chelmsford, Essex, United Kingdom Recruiting -
United Lincolnshire Teaching Hospital NHS Trust
Lincoln, Lincolnshire, United Kingdom Recruiting
Study contacts
- Principal investigator: Astghik Voskanyan, MD — Immune Oncology Research Institute, Yerevan, Armenia
- Study coordinator: Astghik Voskanyan, MD
- Email: astghikvos@gmail.com
- Phone: +374 10 28 38 00
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BPDCN patients treated with chemotherapy: a look back at real-world use
This study tests how chemotherapy has performed in adults with BPDCN and compares the results to a prospective registry for ELZONRIS.
-
Tagraxofusp in BPDCN: Real-world Registry of Safety and Effectiveness
This registry follows adults with BPDCN to see how tagraxofusp works in everyday clinical practice and how safe it is over time.
-
Tagraxofusp and venetoclax in newly diagnosed BPDCN
This trial tests whether combining tagraxofusp with venetoclax can produce higher complete remissions in adults with newly diagnosed BPDCN.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.